Commercial health plans have increased patients ’ out-of-pocket costs by over 50% in some therapeutic areas

According to a recentIQVIA analysis, commercial health plans have increased patients ’ average out-of-pocket costs for brand medicines by over 50% in some therapeutic areas since 2015. Notably, of the seven therapeutic areas that IQVIA analyzed, including anticoagulants, asthma/COPD, depression, diabetes, HIV, multiple sclerosis and oncology treatments, average patient cost exposu re between 2015 and 2019 saw a 32% increase for depression, a 50% increase for HIV and a 56% increase for anticoagulants. Cost exposure represents the level of cost sharing patients would have paid out of pocket if financial assistance, like manufacturer cost-sharing assistance, had not been availab le.
Source: The Catalyst - Category: Pharmaceuticals Authors: Tags: Adherence Drug Cost HIV/AIDS Out-of-Pocket Costs Let's Talk About Cost Source Type: news